skip to Main Content

Payment and Policy Solutions Workgroup

The purpose of this workgroup is to formulate and inform key policy and payment strategies to enable introduction and adoption of a systematic approach to medication use that optimizes clinical outcomes. Reductions in overall cost of care and improved outcomes will be realized by assuring access and affordability of innovative medications—for the right patients. Necessary to this goal will be activities to collect, evaluate and promote widespread (providers/systems, payers and patients) understanding, information sharing, and adoption of contemporary payment reform strategies and methods now occurring in U.S. health care (quality/safety/outcomes/value) and their logical alignment with and essential application to the provision of comprehensive medication management (CMM) services by teams of health care professionals across all settings of care. Model legislation, regulatory guidelines and benefit redesign strategies should be considered in all key areas including CMM implementation, streamlining of clinical trials, access to affordable medications (while preserving innovation), barriers to adoption, payment, clinical use of advanced diagnostics, and AI and IT analytics and data sharing, along with any other area which is necessary to promote a systematic approach to medication optimization.


Kathy Pham headshot

Co-Lead: Kathy Pham, Pharm.D., BCPPS Director, Policy and Professional Affairs, ACCP


John McGlew headshot

Co-Lead: John McGlew, MA, Director of Government Affairs, ACCP


Co-Lead: Brad Cannon, Pharm.D., Director of Experiential Education, Assistant Professor, Department of Pharmacy Practice, Rosalind Franklin University


Co-Lead: Tom Kraus, JD, MHS, VP, Office of Government Relations, ASHP


Workgroup Participants

  • Larry LaMotte, MPP, Principal, Advocacy Option LLC

Areas of Further Work

Create a Value Framework

  • Identify evidence, promising payment frameworks, use case examples and tools for advocacy to promote the value of optimized medication use to consumers, providers, public & private sector payors
  • Offer guidelines and proof points for advocacy that the CMM process offers to showcase and advocate on behalf of appropriate use, decreased waste and optimized outcomes.

Evaluate Barriers to Adoption of New Payment Models

  • Evaluate and establish a plan to overcome policy and payment barriers that currently exist in the market preventing a scalable, sustainable rational system to optimize medication use and gene therapies

Determine Key Policy Elements

  • Identify successful use cases (commercial, public, private) for use in advocacy and coalition building in support of and to advance the mission and vision of GTMRx
  • Specifically define characteristics and foundational elements that will inform a policy  platform designed to overcome barriers to broad

Identify Payment Solutions

  • Identify payment structure solutions (and possible framework) necessary to overcome barriers to adoption of CMM and optimized use of medications and gene therapies.
Back To Top
×Close search